Similar articles

• Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.

  Lein M, Jung K, Brux B, Knäbich A, Sinha P, Schnorr D, Loening SA. Lein M, et al. J Urol. 1999 Aug;162(2):502-3. doi: 10.1016/s0022-5347(05)68613-2. J Urol. 1999. PMID: 10411077 No abstract available.
• Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.

  Benecchi L, Pieri AM, Pastizzaro CD, Potenzoni M. Benecchi L, et al. J Urol. 2011 Mar;185(3):821-6. doi: 10.1016/j.juro.2010.10.077. Epub 2011 Jan 15. J Urol. 2011. PMID: 21238998
• [Prostate-specific antigen. The role in the prostate cancer diagnosis].

  Sánchez-Martínez LC, Paredes-Solís CA, Hernández-Ordóñez OF, Sánchez-Ruvalcaba IR. Sánchez-Martínez LC, et al. Rev Med Inst Mex Seguro Soc. 2013 Mar-Apr;51(2):124-6. Rev Med Inst Mex Seguro Soc. 2013. PMID: 23693096 Spanish.
• [Analysis of recommendations against prostate cancer screening with prostate specific antigen].

  Abascal Junquera JM, Fumadó Ciutat L, Francés Comalat A, Cecchini Rosell L. Abascal Junquera JM, et al. Med Clin (Barc). 2016 Oct 21;147(8):361-365. doi: 10.1016/j.medcli.2016.03.002. Epub 2016 Apr 13. Med Clin (Barc). 2016. PMID: 27085747 Review. Spanish. No abstract available.
• Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.

  Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, Mandarino G, Ward AM, Patel B, Sibley P, Sturgeon C. Price CP, et al. Ann Clin Biochem. 2001 May;38(Pt 3):188-216. doi: 10.1258/0004563011900632. Ann Clin Biochem. 2001. PMID: 11392495 Review. No abstract available.